Cargando…

Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only

BACKGROUND: The prognosis of metastatic colorectal cancer (mCRC) depends on the metastatic site and systemic therapy regimen. Peritoneal metastases are associated with a relatively unfavorable prognosis among patients with mCRC. In this article, we present the treatment outcomes of patients with per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ching-Chun, Chang, Tsung-Kun, Chen, Yen-Cheng, Tsai, Hsiang-Lin, Huang, Ching-Wen, Su, Wei-Chih, Ma, Cheng-Jen, Yin, Tzu-Chieh, Chen, Po-Jung, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045595/ https://www.ncbi.nlm.nih.gov/pubmed/35498511 http://dx.doi.org/10.2147/CMAR.S355318

Ejemplares similares

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
por: Lu, Chien-Yu, et al.
Publicado: (2014)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2016)

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
por: Ma, Cheng-Jen, et al.
Publicado: (2019)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Early penile-only metastasis of urothelial bladder carcinoma
por: Tayeh, Georges Abi, et al.
Publicado: (2020)

Peritoneal carcinomatosis, an unusual and only site of metastasis from lung adenocarcinoma
por: Hanane, Kloub, et al.
Publicado: (2016)

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases
por: Chuang, Shih-Chang, et al.
Publicado: (2020)

Prognostic Factors for Patients with Bone-Only Metastasis in Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Characterization of bone only metastasis patients with respect to tumor subtypes
por: Parkes, Amanda, et al.
Publicado: (2018)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Prognostic Evaluation of Nasopharyngeal Carcinoma with Bone-Only Metastasis after Therapy
por: Lu, Tianzhu, et al.
Publicado: (2016)

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review
por: Li, Yaoyuan, et al.
Publicado: (2022)

Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis
por: Zhang, Li, et al.
Publicado: (2020)

FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
por: Yeh, Yung-Sung, et al.
Publicado: (2014)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis
por: Lin, Cheng, et al.
Publicado: (2022)

Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
por: Delpech, Yann, et al.
Publicado: (2015)

Prognostic significance of bone only metastasis compared to visceral metastasis in patients with carcinoma cervix treated with platinum-based chemotherapy
por: Mallekavu, Suresh Babu, et al.
Publicado: (2017)

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
por: Páez, David, et al.
Publicado: (2018)

Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis
por: Wu, Chun-Xue, et al.
Publicado: (2022)

First Case of the Cervical Lymph Node as the Only Site of Metastasis from Anal Cancer
por: Wang, Bo, et al.
Publicado: (2017)

Burned-out testicular seminoma with retroperitoneal metastasis and contralateral sertoli cell-only syndrome
por: Siokou, Fiona-Sofia, et al.
Publicado: (2022)

Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance
por: Sun, Xue-Song, et al.
Publicado: (2019)

Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis
por: Nong, Sikai, et al.
Publicado: (2020)

Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy
por: Saif, Muhammad Wasif, et al.
Publicado: (2010)

Bilateral metastasis to the femoral head as the only manifestation of recurrence of gastric adenocarcinoma: a case report
por: Fernández-Aceñero, Ma Jesus, et al.
Publicado: (2003)

Unusual Case of Neuroblastoma with Only Growth Plate Metastasis in Bilateral Lower Limbs on Metaiodobenzylguanidine Scintigraphy
por: Yadav, Naveen, et al.
Publicado: (2021)

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study
por: Shi, Hon-Yi, et al.
Publicado: (2022)

Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation
por: Biebighauser, K.C., et al.
Publicado: (2017)

Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
por: Park, Soyeon, et al.
Publicado: (2017)

No best, only better: another APSTH milestone
por: Shen, Ming-Ching
Publicado: (2016)

Survival nomograms for colorectal carcinoma patients with lung metastasis and lung-only metastasis, based on the SEER database and a single-center external validation cohort
por: Liu, Lin-Lin, et al.
Publicado: (2022)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Long-Term Treatment Outcome after Only Popliteal Lymph Node Dissection for Nodal Metastasis in Malignant Melanoma of the Heel: The Only “Interval Node” Dissection Can Be an Adequate Surgical Treatment
por: Tanaka, Kentaro, et al.
Publicado: (2013)

Only 2
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4481opibu6orn2qiml5gfft41g